Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(21):1570-1572; doi:10.1093/jnci/96.21.1570
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McBride, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McBride, G.
Related Collections
Right arrowRelated News Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Researchers Optimistic About Targeted Drugs for Pancreatic Cancer

Gail McBride

The first 10% of the full text of this article appears below.

A number of investigational targeted therapies are being tested in pancreatic cancer in hopes of finding an effective treatment for a disease that has nearly equal incidence and mortality rates and that has few treatment options. At the same time, some researchers warn that proceeding with these various trials—some whose quality should be questioned—without systematically considering the results serves only to hurt the field.

The goal of a number of new trials in pancreatic cancer is to target the stroma—the matrix or supporting tissue of an organ—and its importance in the development, maintenance, and response to therapy of pancreatic ductal adenocarcinomas. Several studies of agents that may target the stroma were discussed at the recent Pancreatic Cancer 2004 conference in San Francisco, sponsored by the Lustgarten Foundation for Pancreatic Cancer Research, the American Association for Cancer Research, and the . . . [Full Text of this Article]

Trial Designs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related News Article in JNCI

Screening Methods May Offer Early Diagnosis of Pancreatic Cancer
Gail McBride
J Natl Cancer Inst 2004 96: 1571. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
Z. Jia, J. Zhang, D. Wei, L. Wang, P. Yuan, X. Le, Q. Li, J. Yao, and K. Xie
Molecular Basis of the Synergistic Antiangiogenic Activity of Bevacizumab and Mithramycin A
Cancer Res., May 15, 2007; 67(10): 4878 - 4885.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke
Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Korpanty, J. G. Carbon, P. A. Grayburn, J. B. Fleming, and R. A. Brekken
Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
Clin. Cancer Res., January 1, 2007; 13(1): 323 - 330.
[Abstract] [Full Text] [PDF]